期刊文献+

酵母浸出粉在奈瑟脑膜炎双球菌培养中的比较观察 被引量:3

Observation on effect of yeast extract in the medium for culture of Neisseria menigitids
暂未订购
导出
摘要 目的探索A群,C群奈瑟脑膜炎双球菌(简称流脑)多糖疫苗生产中奈瑟脑膜炎双球菌培养的最适培养基。方法在培养基配制中用增减酵母浸出粉的方法制备相应的培养基,8h收菌,通过菌体的收获量并参考多糖量来确定较好的培养基配比。结果不同培养基用于A群、C群奈瑟脑膜炎菌培养8h后均有收获,其中2号培养基(酵母浸出粉)培养的菌体的浓度明显高于1号和3号培养基,它们之间有显著性差异(P<0.05)此种培养基能提高奈瑟脑膜炎双球菌的产量。结论添加酵母浸出粉的培养基可作为A群、C群奈瑟脑膜炎双球菌培养的最适培养基。 Objective To explore the optimal medium for culture of group A and group C Neisseria menigitids in production of Meningococas polysaccharide vaccine. Methods The yeast extract was changed by adjusting its content in the tested medium, the Neisseria meningitids was cultivated for eight hours and then harvested, the best formulation of the medium was selected in comparison of obtained amount of bacterial cells and polysaccharides. Results The obtained amount of bacterial ceils was apparently higher in the medium with improved yeast extraction powder( NO. 2 medium) by comparing those cultured from NO. 1 medium and NO. 3 medium, there was a significant deference in NO. 2, NO. 1, and NO. 3 medium ( P〈0.05). Conclusion NO. 2 medium was selected as the optimal formulation used in cultivation of group A and group C Neisseria meningitids.
出处 《微生物学免疫学进展》 2012年第5期20-23,共4页 Progress In Microbiology and Immunology
关键词 酵母浸出粉 奈瑟脑膜炎双球菌 培养基 培养菌数 Yeast extract Neisseria menigitids Medium Bacterial concentration
  • 相关文献

参考文献12

  • 1王金风,丁峥嵘.流行性脑脊髓膜炎防治研究进展[C]//.第十次全国生物制品学术会议论文汇编.2008-2009.P108-111.
  • 2Plotkin SA,Orenstein WA.Vaccines[M].3rd.Philadelphia:Saun-ders,1999:711-727.
  • 3Jodar L,Feavers IM,Salisbury D,et al.Development of vaccines a-gainst meningococcal disease[J].Lancet,2002,359:1499-1508.
  • 4胡绪敬.流脑流行的监测与预防[J].中国公共卫生,2004,20(5):638-640. 被引量:115
  • 5卫生部.2006年全国法定传染病疫情[EB/OL].卫生部,中华人民共和国.http://www.chinacdc.net.cn/n272442/n272530/n272757.16423.html.
  • 6李国宴,孙一枚,杨勇,等.脑膜炎奈瑟氏菌培养结果与培养基质量指标的关系研究[C].第十次全国生物制品学术会议论文汇编.2008-2009:119-122.
  • 7李国晏,孙一玫,吴卫坚,闫效新.脑膜炎球菌多糖疫苗培养基的标准化研究[J].微生物学免疫学进展,2012,40(2):26-29. 被引量:5
  • 8国家药典委员会,编.中华人民共和国药典三部2005年版[S].北京:化学工业出版社,2005.
  • 9杨建勇,刘梅影,林云,张达伦,王复禄,吕世泽,陈云,张燕斌,单璞,王建华.W135群脑膜炎球菌发酵工艺的研究[J].微生物学免疫学进展,2005,33(3):19-24. 被引量:9
  • 10胡丽娜,魏东.重组鼠疫菌LcrV抗原的制备工艺研究[C].第十次全国生物制品学术会议论文汇编.2008-2009:182-190.

二级参考文献16

  • 1李德好,胡绪敬,徐丽,程晋,胡乐华,谭绪健.脑膜炎奈瑟氏菌对常用抗菌药物敏感性监测[J].疾病监测,1996,11(11):405-407. 被引量:8
  • 2国家药典委员会,编.中华人民共和国药典三部2005年版[S].北京:化学工业出版社,2005.
  • 3WHO Health Organization. Meningococcal diseasa,serogroup W135[J].WKLY Epidemiol Rec 2002,76:141-142.
  • 4Jodar L,Feavers IM,Salisburu D,et al. Development of vaccines against meningococcal disease[J]. Lancet.2002,359(9316):1499-1508.
  • 5WHO:Require of polysaccharide vaccinum of meningococcus[M].TRS No.594.45.
  • 6MacLennan J M, Heath P T, Deeks J J, et al. Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants[J].JAMA, 2000, 283(21) :2795.
  • 7Maiden MCJ, Stuart J M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination[J]. Lancet, 2002, 359:1829.
  • 8Robbins J B, Schneerson R, Gotschlich EC, et al. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines [ J ]. WHO,2003, 81(10) :745.
  • 9Noah N. Surveillance of bacterial meningitis in Europe 1999/2000. (in press).
  • 10Wider - Smith A, Barkham TMS, Ravindran S, et al. Persistence of W135 Neisseria meningitidis carriage in returning Hajj Pilgrims:risk for early and late transmission to housahold contacts[J]. Emerging Inf Dis, 2003, 9(1): 123.

共引文献121

同被引文献49

引证文献3

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部